Association between fingertip-measured advanced glycation end products and cardiovascular events in outpatients with cardiovascular disease
Main finding · MACCEResult — go to the resultHazard ratio 2.638 95% CI 1.271–5.471Authors' conclusion
AGEs score measured at the fingertip in patients with CVD is associated with MACCE. AGEs score, which can be measured noninvasively and easily, may be useful as an assessment for the secondary prevention of CVD in patients with CVD.
Study context
- Population
- Outpatients with cardiovascular disease (CVD); AGEs measured noninvasively at the fingertip with an AGEs sensor
- Participants
- 191 outpatients
- Exposure
- High vs low AGEs score
- Outcome
- Incidence of MACCE:
- Cardiac death
- MI
- Percutaneous coronary intervention
- HF
- Stroke
- Follow-up
- 30 months
Main finding
MACCE
Hazard ratio
2.638
95% CI 1.271–5.471
P = 0.009
By group
High-AGEs scorevs Low-AGEs score
HR 2.638 (95% CI 1.271–5.471); P = 0.009
As reported in the abstract
Observational data: associations, not effects.
Further findings
AGEs score cutoff for detection of major adverse cardiovascular and cerebrovascular events (MACCE) (ROC)
- Best cutoff AGEs score
- 0.51
- AUC
- 0.642
- P
- P = 0.008
- Sensitivity
- 72.2%
- Specificity
- 54.8%
AGEs score distribution
- Median AGEs score (normally distributed)
- 0.51
- No significant intergroup differences in laboratory findings, physical functions or medications
Original publication
Association between fingertip-measured advanced glycation end products and cardiovascular events in outpatients with cardiovascular disease. Cardiovasc Diabetol. Published 17 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →